Objective:To observe the efficacy and toxicity of domestic epirubicin in treatment of non Hodgkin's lymphoma, breast cancer, and non small cell lung cancer.
目的：观察国产表柔比星为主的联合化疗方案治疗非霍奇金淋巴瘤、乳腺癌、非小细胞肺癌的疗效和不良反应。
Methods: 9 patients with pathologically confirmed high risk breast cancer, lymphoma, and small cell lung cancer, previously treated with chemotherapy were treated with this procedure.
方法：9例经病理确诊的高危乳腺癌、淋巴瘤及小细胞肺癌在经不同程度的化疗后，进行了大剂量化疗并自体外周血干细胞的移植。
The research also showed a small link with a very rare form of cancer known as anaplastic large cell lymphoma.
研究还指出隆胸手术和一种名为间变性大细胞淋巴瘤的罕见的癌症形式之间的细微联系。
The pathologic diagnosis was diffuse small cleaved cell lymphoma.
病理诊断为弥漫小核裂细胞型。
Histologically, 5 of 9 cases were polymorphoral(peripheral) T cell lymphoma, in the rest 4 of B cell lymphoma, 2 were lymphoplasmacytoid and the other 2 were small cell type.
组织学上多形T细胞淋巴瘤5例，B细胞淋巴瘤4例，其中淋巴浆细胞样型和小细胞性各2例。
Others drugs Novartis aims to launch by 2011 are ASA404 for non-small-cell lung cancer, SOM230 for a rare group of neuroendocrine tumors and LBH589 for cutaneous T-cell lymphoma.
2011年前诺华公司想要发布的其他药物是治疗非小细胞肺癌的ASA404，治疗一种罕见消化系统神经内分泌癌的SOM230和治疗皮肤T细胞淋巴瘤的LBH589。
Results (1) Of the 24 intestinal T cell lymphoma cases, 23 were pleomorphic, medium to large cell type, and one cases was small cell type;
结果（1）24例肠道T细胞淋巴瘤，23 例为多形细胞，中等至大细胞性，1 例为小细胞性；
BRISH light chain restriction (LCR) results were concordant with FCM in 108 (99%) of 109 evaluable cases. Additional small B-cell lymphoma cohorts were successfully evaluated.
在109例可评价的病例中，有108例(99%)BRISH检测轻链限制性(LCR)的结果与流式细胞仪一致，并成功评估了另外的小B细胞淋巴瘤病例组。
BRISH light chain restriction (LCR) results were concordant with FCM in 108 (99%) of 109 evaluable cases. Additional small B-cell lymphoma cohorts were successfully evaluated.
在109例可评价的病例中，有108例(99%)BRISH检测轻链限制性(LCR)的结果与流式细胞仪一致，并成功评估了另外的小B细胞淋巴瘤病例组。
应用推荐